Keyword Analysis & Research: dicerna
Keyword Research: People who searched dicerna also searched
Search Results related to dicerna on Search Engine
-
Novo Nordisk to Acquire Dicerna | Business Wire
https://www.businesswire.com/news/home/20211118005644/en/Novo-Nordisk-to-Acquire-Dicerna
WEBNov 18, 2021 · DRNA announces definitive agreement with Novo Nordisk to be acquired for $38.25 per share in cash, which represents total equity value of $3.3 billion. Dicerna Pharmaceuticals. Media: Amy...
DA: 54 PA: 69 MOZ Rank: 15
-
News Details - Novo Nordisk
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=87435
WEBBagsværd, Denmark, 18 November 2021 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms and supports the ...
DA: 71 PA: 67 MOZ Rank: 96
-
Dicerna’s GalXC-Plus™ RNAi Technology Delivers ... - Business Wire
https://www.businesswire.com/news/home/20210330005357/en/Dicerna%E2%80%99s-GalXC-Plus%E2%84%A2-RNAi-Technology-Delivers-Target-Knockdown-Across-CNS-and-to-Specific-CNS-Cell-Types-in-Preclinical-Studies
WEBMar 30, 2021 · Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies. March 30, 2021 10:50 AM Eastern Daylight Time. LEXINGTON,...
DA: 64 PA: 16 MOZ Rank: 84
-
News Details - Novo Nordisk
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=93736
WEBBagsværd, Denmark, 28 December 2021 – Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals (Dicerna), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a ...
DA: 91 PA: 48 MOZ Rank: 70
-
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals
https://www.businesswire.com/news/home/20211227005121/en/Novo-Nordisk-Announces-Completion-of-Dicerna-Pharmaceuticals-Acquisition
WEBDec 28, 2021 · LEXINGTON, Mass.-- ( BUSINESS WIRE )--Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.
DA: 29 PA: 90 MOZ Rank: 94
-
Dicerna Pharmaceuticals, Inc. | LinkedIn
https://www.linkedin.com/company/dicerna-pharmaceuticals-inc./
WEBDicerna Pharmaceuticals, Inc. | 30,683 followers on LinkedIn. Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to ...
DA: 45 PA: 76 MOZ Rank: 34
-
Novo to acquire Dicerna for more than $3B amid RNA drug …
https://www.biopharmadive.com/news/novo-dicerna-rnai-acquire-deal/610254/
WEBNov 18, 2021 · Ben Fidler Senior Editor. Novo Nordisk. Diabetes drug specialist Novo Nordisk has agreed to acquire Dicerna Pharmaceuticals in a deal worth $3.3 billion, a strategic bet that an existing wide-ranging alliance between the two will yield multiple medicines for a range of diseases. Novo will pay $38.25 per share in cash for Dicerna, an 80% premium ...
DA: 48 PA: 99 MOZ Rank: 10
-
Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To …
https://finance.yahoo.com/news/novo-nordisk-swallows-dicerna-3-142816889.html
WEBNov 18, 2021 · Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% ...
DA: 21 PA: 16 MOZ Rank: 62
-
Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion
https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/
WEBNov 18, 2021 · Danish drugmaker Novo Nordisk has agreed a $3.3 billion cash deal to buy Dicerna Pharmaceuticals which specializes in therapeutics that counteract disease-causing genes, it said on Thursday.
DA: 19 PA: 28 MOZ Rank: 11
-
Novo Nordisk to acquire biopharmaceutical company Dicerna for …
https://www.pharmaceutical-technology.com/news/novo-nordisk-acquire-dicerna/
WEBNov 19, 2021 · Dicerna leverages GalXC and GalXC-Plus RNAi technologies to develop RNAi-based treatments that are claimed to specifically silence disease-causing genes. Its RNAi technology platform provides access to intracellular disease targets in hepatic, as well as extrahepatic cell and tissue types.
DA: 51 PA: 49 MOZ Rank: 29